Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $82
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has maintained a Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) and increased the price target from $72 to $82.
February 23, 2024 | 11:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia reaffirmed a Buy rating on Intra-Cellular Therapies and raised the price target from $72 to $82.
The increase in price target by a reputable analyst like Ami Fadia from Needham is a strong positive signal for Intra-Cellular Therapies. Such endorsements often lead to increased investor confidence and can drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100